TITLE

Autocrine human growth hormone expression leads to resistance of MCF-7 cells to tamoxifen

AUTHOR(S)
Mojarrad, Majid; Momeny, Majid; Mansuri, Fatemeh; Abdolazimi, Yassan; Tabrizi, Mina Hajifaraj; Ghaffari, Seyed Hamidollah; Tavangar, Seyed Mohammad; Modarressi, Mohammad Hussein
PUB. DATE
June 2010
SOURCE
Medical Oncology;Jun2010, Vol. 27 Issue 2, p474
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Tamoxifen is the most common antiestrogen used in the treatment of estrogen-positive breast cancer but its adverse effects and also resistance to this drug are serious challenges in the treatment of breast cancer. Characterization of mechanisms responsible for these adverse effects can lead to design of more efficient therapeutic strategies for the treatment of breast cancer. Here, we used a cellular model to evaluate the effects of autocrine expression of human growth hormone on responses of cells to tamoxifen. Our results imply for the first time that autocrine expression of growth hormone in human breast adenocarcinoma cell line, MCF-7, results in increase in cell proliferative capacity of cells even in the presence of tamoxifen. This effect may be due to up-regulation of G-coupled estrogen receptor, GPR30, which is activated by tamoxifen.
ACCESSION #
50107461

 

Related Articles

  • Tamoxifen Update. Sugerman, Deborah Tolmach // JAMA: Journal of the American Medical Association;8/28/2013, Vol. 310 Issue 8, p866 

    The article provides information on the drug Tamoxifen. Tamoxifen is a drug that blocks the effects of the hormone estrogen. It is used as a treatment for breast cancer patients whose tumors have estrogen receptors, called ER positive. It is often used after surgery or radiation therapy and also...

  • The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer. Yan Ni Loh; Hedditch, Ellen L.; Baker, Laura A.; Jary, Eve; Ward, Robyn L.; Ford, Caroline E. // BMC Cancer;2013, Vol. 13 Issue 1, p1 

    Background: Acquired resistance to Tamoxifen remains a critical problem in breast cancer patient treatment, yet the underlying causes of resistance have not been fully elucidated. Abberations in the Wnt signalling pathway have been linked to many human cancers, including breast cancer, and...

  • Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer. Larsen, Sarah L.; Yde, Christina W.; Laenkholm, Anne-Vibeke; Rasmussen, Birgitte B.; Duun-Henriksen, Anne Katrine; Bak, Martin; Lykkesfeldt, Anne E.; Kirkegaard, Tove // BMC Cancer;2015, Vol. 15 Issue 1, p1 

    Background: Resistance to antiestrogen therapy is a major clinical challenge in the treatment of estrogen receptor α (ER)-positive breast cancer. The aim of the study was to explore the growth promoting pathways of antiestrogen resistant breast cancer cells to identify biomarkers and novel...

  • Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells. Woo, Yu Mi; Shin, Yubin; Lee, Eun Ji; Lee, Sunyoung; Jeong, Seung Hun; Kong, Hyun Kyung; Park, Eun Young; Kim, Hyoung Kyu; Han, Jin; Chang, Minsun; Park, Jong-Hoon // PLoS ONE;7/9/2015, Vol. 10 Issue 7, p1 

    Tamoxifen resistance is often observed in the majority of estrogen receptor–positive breast cancers and it remains as a serious clinical problem in breast cancer management. Increased aerobic glycolysis has been proposed as one of the mechanisms for acquired resistance to chemotherapeutic...

  • XIAP inhibitor and antiestrogen embelin abrogates metastasis and augments apoptosis in estrogen receptor positive human breast adenocarcinoma cell line MCF-7. Sumalatha, K.; Abiramasundari, G.; Chetan, G.; Divya, T.; Sudhandiran, G.; Sreepriya, M. // Molecular Biology Reports;Feb2014, Vol. 41 Issue 2, p935 

    Tamoxifen therapy for the treatment of hormone responsive breast cancer has limitations due to acquired resistance in the case of recurrences. Embelin, a known inhibitor of X-linked inhibitor of apoptosis protein (XIAP) was also reported to exhibit strong antiestrogenic effects in animal models....

  • MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Rao, X; Di Leva, G; Li, M; Fang, F; Devlin, C; Hartman-Frey, C; Burow, M E; Ivan, M; Croce, C M; Nephew, K P // Oncogene;3/3/2011, Vol. 30 Issue 9, p1082 

    Fulvestrant is a selective estrogen receptor downregulator (SERD) and highly effective antagonist to hormone-sensitive breast cancers following failure of previous tamoxifen or aromatase inhibitor therapies. However, after prolonged fulvestrant therapy, acquired resistance eventually occurs in...

  • Fulvestrant: A Viewpoint by Roger W. Blamey. Blamey, R.W. // Drugs;Apr2001, Vol. 61 Issue 6, p814 

    Presents information on fulvestrant, an anti-estrogen antagonist, indicated for treating breast cancer. Comparison between fulvestrant and tamoxifen as estrogen receptors; Limitations of the effect of the fulvestrant.

  • Tamoxifen induction of apoptosis in estrogen receptor-negative cancers: New tricks for an old dog? Gelmann, Edward P. // JNCI: Journal of the National Cancer Institute;3/6/96, Vol. 88 Issue 5, p224 

    Editorial. Describes the efficacy of tamoxifen induction of apoptosis in estrogen receptor-negative breast cancer. Result of combined cytotoxic and hormonal therapy; Comparison with chemotherapy in adjuvant therapy for breast cancer; Tamoxifen's efficacy in glioma and melanoma; Effect of...

  • AIB1 expression predicted response to tamoxifen treatment in postmenopausal women.  // Hem/Onc Today;9/10/2013, Vol. 14 Issue 17, p4 

    The article discusses a study published in a 2013 issue of the "Annals of Oncology" that looked into whether high levels of the estrogen receptor co-activator amplified in breast cancer 1 (AIB1) can predict response to tamoxifen treatment among postmenopausal women with breast cancer.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics